- Home
- PD vs RCKT Comparison
PD vs RCKT Comparison
Compare PD & RCKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PD | RCKT |
|---|---|---|
| Founded | 2009 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 340.9M |
| IPO Year | 2019 | N/A |
Fundamental Metrics
Financial Performance| Metric | PD | RCKT |
|---|---|---|
| Price | $13.52 | $3.48 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 10 | 14 |
| Target Price | $17.70 | ★ $29.12 |
| AVG Volume (30 Days) | ★ 2.1M | 1.9M |
| Earning Date | 11-25-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.63 | N/A |
| Revenue | ★ $489,207,000.00 | N/A |
| Revenue This Year | $8.16 | N/A |
| Revenue Next Year | $3.88 | N/A |
| P/E Ratio | $8.08 | ★ N/A |
| Revenue Growth | ★ 7.01 | N/A |
| 52 Week Low | $11.13 | $2.19 |
| 52 Week High | $20.00 | $13.35 |
Technical Indicators
Market Signals| Indicator | PD | RCKT |
|---|---|---|
| Relative Strength Index (RSI) | 52.31 | 53.27 |
| Support Level | $12.69 | $3.19 |
| Resistance Level | $13.11 | $3.60 |
| Average True Range (ATR) | 0.37 | 0.19 |
| MACD | 0.17 | 0.02 |
| Stochastic Oscillator | 94.00 | 59.78 |
Price Performance
Historical ComparisonAbout PD PagerDuty Inc.
PagerDuty Inc is a digital operations management platform that manages urgent and mission-critical work for a modern, digital business. Its PagerDuty Operations Cloud combines artificial intelligence (AI) operations (AIOps), automation, customer service operations, and incident management with a generative AI assistant to create a flexible, resilient, and scalable platform to protect revenue and improve customer experience, improve operational efficiency, and mitigate the risk of operational failures. The company generates revenue predominantly from cloud-hosted software subscription fees and term-license software subscription fees. Geographically, the firm derives a majority of its revenue from the United States and the rest from International markets.
About RCKT Rocket Pharmaceuticals Inc.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. The Company has one reportable segment related to R&D and commercial readiness of its gene therapies.